IGF1 and neoplasm: We have also shown that tumor development in liver-specific IGF-1 deficient (LID) mice, which have a ∼75% reduction in systemic IGF-1 levels relative to wild-type mice, is inhibited to levels observed in wild-type mice on a CR regimen [10, 11].